ReShape Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . ReShape Lifesciences
RSLS Stock  USD 3.77  0.08  2.08%   
ReShape Lifesciences financial statements provide useful quarterly and yearly information to potential ReShape Lifesciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ReShape Lifesciences financial statements helps investors assess ReShape Lifesciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ReShape Lifesciences' valuation are summarized below:
Gross Profit
6.8 M
Profit Margin
(1.12)
Market Capitalization
3.6 M
Enterprise Value Revenue
0.2755
Revenue
8 M
There are over one hundred nineteen available trending fundamental ratios for ReShape Lifesciences, which can be analyzed over time and compared to other ratios. All traders should check out ReShape Lifesciences' recent fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 1.6 M in 2025. Enterprise Value is likely to gain to about (3 M) in 2025

ReShape Lifesciences Total Revenue

5.37 Million

Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 22.2 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many indicators such as Price To Sales Ratio of 0.19, Dividend Yield of 0.0 or PTB Ratio of 0.24. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
  
Check out the analysis of ReShape Lifesciences Correlation against competitors.
For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

ReShape Lifesciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets11.6 M12.3 M26.9 M
Very volatile
Other Assets111.4 K117.3 K2.9 M
Very volatile
Common Stock Shares Outstanding128.9 K92.4 K183.1 K
Slightly volatile
Liabilities And Stockholders Equity11.6 M12.3 M26.9 M
Very volatile
Other Stockholder Equity775.6 M738.6 M423.1 M
Slightly volatile
Total Liabilities4.4 M4.6 M9.6 M
Pretty Stable
Short and Long Term Debt Total224 K235.8 K4 M
Slightly volatile
Total Current Liabilities6 M4.3 M5.6 M
Pretty Stable
Property Plant And Equipment Net265.1 K279 K577.3 K
Very volatile
Accounts Payable1.3 M1.9 M1.5 M
Slightly volatile
Cash3.8 M4 M10.5 M
Slightly volatile
Non Current Assets Total400.9 K422.1 K12.8 M
Pretty Stable
Non Currrent Assets Other31.7 K33.4 K517.5 K
Slightly volatile
Cash And Short Term Investments3.8 M4 M10.6 M
Slightly volatile
Net Receivables997.2 K1.9 M1.1 M
Slightly volatile
Common Stock Total Equity6.6 K6.9 K166.4 K
Slightly volatile
Non Current Liabilities Total190.7 K200.7 K4.8 M
Slightly volatile
Other Current Assets373.6 K393.3 K898.4 K
Very volatile
Property Plant And Equipment Gross618.1 K360 K630.7 K
Pretty Stable
Total Current Assets16.2 M9.3 M14.9 M
Slightly volatile
Short Term Debt94.9 K99.9 K1.9 M
Slightly volatile
Common Stock19.7 K20.7 K169.7 K
Slightly volatile
Property Plant Equipment565.6 K782.1 K586 K
Pretty Stable
Other Liabilities934.1 K983.2 K2.3 M
Pretty Stable
Long Term Debt Total11.1 M10.5 M5.5 M
Slightly volatile
Capital Surpluse386.1 M608.8 M387.3 M
Slightly volatile
Short and Long Term Debt2.7 M4.2 M3.2 M
Slightly volatile
Non Current Liabilities Other933.4 K1.1 M1.7 M
Slightly volatile
Net Invested Capital5.7 M6 M46.8 M
Slightly volatile
Capital Stock18.5 K20.7 K55.4 K
Slightly volatile
Capital Lease Obligations313.1 K235.8 K588.6 K
Slightly volatile

ReShape Lifesciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses26.5 M26.8 M26.3 M
Slightly volatile
Selling General Administrative14.4 M9.3 M15.4 M
Pretty Stable
Research Development2 M2.1 M6.3 M
Slightly volatile
Interest Income9119593.1 K
Slightly volatile
Reconciled Depreciation1.5 M761.3 K1.1 M
Slightly volatile
Selling And Marketing Expenses8.4 M8.7 M6.5 M
Slightly volatile
Non Recurring8.8 M7.3 M11.4 M
Slightly volatile

ReShape Lifesciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.4 M3.6 M11.8 M
Slightly volatile
Depreciation168.2 K177.1 K670.5 K
Slightly volatile
Capital Expenditures36.8 K38.7 K158 K
Slightly volatile
Total Cash From Financing Activities16.7 M15.8 M18 M
Very volatile
End Period Cash Flow3.9 M4.1 M10.5 M
Slightly volatile
Stock Based Compensation836.9 K880.9 K3.7 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.190.210.9 K
Slightly volatile
Days Sales Outstanding14280.24111
Pretty Stable
Average Payables1.3 M1.2 M986.5 K
Slightly volatile
Stock Based Compensation To Revenue0.09640.17.8177
Slightly volatile
Capex To Depreciation0.310.320.5698
Slightly volatile
Inventory Turnover0.910.750.8513
Slightly volatile
Days Of Inventory On Hand4775021.7 K
Slightly volatile
Payables Turnover0.891.671.03
Slightly volatile
Sales General And Administrative To Revenue1.31.3712.6565
Slightly volatile
Research And Ddevelopement To Revenue0.290.3113.032
Slightly volatile
Capex To Revenue0.00540.00570.0893
Slightly volatile
Cash Per Share47.4349.9343.3 K
Slightly volatile
Days Payables Outstanding215226615
Pretty Stable
Income Quality1.81.710.8552
Slightly volatile
Intangibles To Total Assets0.02550.02680.5842
Slightly volatile
Current Ratio2.983.1315.5375
Pretty Stable
Receivables Turnover4.736.024.7324
Pretty Stable
Graham Number344362266.1 K
Pretty Stable
Debt To Equity0.0430.04520.4411
Slightly volatile
Capex Per Share0.460.48352
Slightly volatile
Average Receivables664.2 K632.5 K490.8 K
Slightly volatile
Revenue Per Share92.3297.173.3 K
Very volatile
Interest Debt Per Share2.792.9313.8 K
Slightly volatile
Debt To Assets0.02680.02830.1327
Slightly volatile
Operating Cycle5535821.8 K
Slightly volatile
Days Of Payables Outstanding215226615
Pretty Stable
Ebt Per Ebit1.090.71.3873
Pretty Stable
Long Term Debt To Capitalization0.340.450.3549
Very volatile
Total Debt To Capitalization0.04130.04350.1752
Slightly volatile
Debt Equity Ratio0.0430.04520.4411
Slightly volatile
Quick Ratio1.92.014.3929
Pretty Stable
Net Income Per E B T0.870.91.0307
Very volatile
Cash Ratio1.291.3613.7429
Pretty Stable
Days Of Inventory Outstanding4775021.7 K
Slightly volatile
Days Of Sales Outstanding14280.24111
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.151.0272
Slightly volatile
Fixed Asset Turnover26.4525.199.4597
Slightly volatile
Debt Ratio0.02680.02830.1327
Slightly volatile
Price Sales Ratio0.190.210.9 K
Slightly volatile
Asset Turnover0.770.730.2818
Slightly volatile
Gross Profit Margin0.420.580.498
Slightly volatile

ReShape Lifesciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.6 M1.7 M2 B
Slightly volatile

ReShape Fundamental Market Drivers

Cash And Short Term Investments4.5 M

ReShape Upcoming Events

23rd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About ReShape Lifesciences Financial Statements

ReShape Lifesciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may analyze each financial statement separately, they are all interrelated. The changes in ReShape Lifesciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on ReShape Lifesciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue50.6 K53.1 K
Total Revenue10 M5.4 M
Cost Of Revenue3.6 M2.2 M
Stock Based Compensation To Revenue 0.10  0.10 
Sales General And Administrative To Revenue 1.37  1.30 
Research And Ddevelopement To Revenue 0.31  0.29 
Capex To Revenue 0.01  0.01 
Revenue Per Share 97.17  92.32 
Ebit Per Revenue(1.52)(1.59)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY